Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that members of its management team are scheduled to participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022.
These representatives of the company will conduct a presentation beginning at approximately 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time).
A live webcast of the session will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. A replay of the webcast will be accessible at the same location beginning approximately one hour following the completion of the event.
Fulgent is a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology. Its proprietary technology platform for genetics has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Fulgent’s therapeutics business is fully focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company focused on oncology.
Investor Relations Contacts:
The Blueshirt Group
Melanie Solomon, firstname.lastname@example.org